The importance of the innate immune system in the development of atherosclerosis is demonstrated by the results of the canakinumab study (CANTOS) showing that anti-inflammatory therapy targeting IL-1β leads to a reduced rate of recurrent cardiovascular events in patients with sustained myocardial infarction, which is not dependent on lipid lowering [91]. This evidence concerns the gene IL1B and atherosclerosis.